Cargando…

Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia

BACKGROUND: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu Qian, Kwong, Yok Lam, Wong, Kit Fai, Kho, Chi Shan Bonnie, Jin, Dong Yan, Tse, Eric, Rosèn, Anders, Chim, Chor Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941938/
https://www.ncbi.nlm.nih.gov/pubmed/24559316
http://dx.doi.org/10.1186/1479-5876-12-52
_version_ 1782306000796123136
author Wang, Lu Qian
Kwong, Yok Lam
Wong, Kit Fai
Kho, Chi Shan Bonnie
Jin, Dong Yan
Tse, Eric
Rosèn, Anders
Chim, Chor Sang
author_facet Wang, Lu Qian
Kwong, Yok Lam
Wong, Kit Fai
Kho, Chi Shan Bonnie
Jin, Dong Yan
Tse, Eric
Rosèn, Anders
Chim, Chor Sang
author_sort Wang, Lu Qian
collection PubMed
description BACKGROUND: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203 or miR-124-1 methylation in CLL. METHODS: miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78 diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with 5-Aza-2’-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells. RESULTS: miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines. miR-34b/c expression was inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c, including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. 5-Aza-2’-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells. Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL. CONCLUSIONS: Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study.
format Online
Article
Text
id pubmed-3941938
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39419382014-03-05 Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia Wang, Lu Qian Kwong, Yok Lam Wong, Kit Fai Kho, Chi Shan Bonnie Jin, Dong Yan Tse, Eric Rosèn, Anders Chim, Chor Sang J Transl Med Research BACKGROUND: TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation might correlate with miR-203 or miR-124-1 methylation in CLL. METHODS: miR-34b/c, miR-34a and DAPK1 methylation was studied in 11 normal controls, 7 CLL cell lines, and 78 diagnostic CLL samples by methylation-specific polymerase chain reaction. MEC-1 cells were treated with 5-Aza-2’-deoxycytidine for reversal of methylation-associated miRNA silencing. Tumor suppressor properties of miR-34b were demonstrated by over-expression of precursor miR-34b in MEC-1 cells. RESULTS: miR-34b/c promoter was unmethylated in normal controls, but completely methylated in 4 CLL cell lines. miR-34b/c expression was inversely correlated with miR-34b/c methylation. Different MSP statuses of miR-34b/c, including complete methylation and complete unmethylation, were verified by quantitative bisulfite pyrosequencing. 5-Aza-2’-deoxycytidine treatment resulted in promoter demethylation and miR-34b re-expression in MEC1 cells. Moreover, over-expression of miR-34b resulted in inhibition of cellular proliferation and increased cell death. In primary CLL samples, miR-34a, miR-34b/c and DAPK1 methylation was detected in 2.6%, 17.9% and 34.6% of patients at diagnosis respectively. Furthermore, 39.7%, 3.8% and 2.6% patients had methylation of one, two or all three genes respectively. Overall, 46.2% patients had methylation of at least one of these three genes. Besides, miR-34b/c methylation was associated with methylation of miR-34a (P = 0.03) and miR-203 (P = 0.012) in CLL. CONCLUSIONS: Taken together, miR-34b/c is a tumor suppressor miRNA frequently methylated, and hence silenced in CLL. Together with DAPK1 methylation, miR-34b/c methylation is implicated in the disruption of the TP53-centered tumor suppressor network. Moreover, the association of miRNA methylation warrants further study. BioMed Central 2014-02-22 /pmc/articles/PMC3941938/ /pubmed/24559316 http://dx.doi.org/10.1186/1479-5876-12-52 Text en Copyright © 2014 Wang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Lu Qian
Kwong, Yok Lam
Wong, Kit Fai
Kho, Chi Shan Bonnie
Jin, Dong Yan
Tse, Eric
Rosèn, Anders
Chim, Chor Sang
Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title_full Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title_fullStr Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title_full_unstemmed Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title_short Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia
title_sort epigenetic inactivation of mir-34b/c in addition to mir-34a and dapk1 in chronic lymphocytic leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941938/
https://www.ncbi.nlm.nih.gov/pubmed/24559316
http://dx.doi.org/10.1186/1479-5876-12-52
work_keys_str_mv AT wangluqian epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT kwongyoklam epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT wongkitfai epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT khochishanbonnie epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT jindongyan epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT tseeric epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT rosenanders epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia
AT chimchorsang epigeneticinactivationofmir34bcinadditiontomir34aanddapk1inchroniclymphocyticleukemia